, with inconsistent use of measurement thresholds
and a lack of data examining the effect of combining
test outcomes. New technologies to develop optimal
tools and measures of foot perfusion for people with
DFU and PAD to guide revascularisation therapies would
be invaluable in guiding revascularisation strategies for
individuals and for determining when more aggressive
strategies are indicated.
Further questions. Which group of people with diabetes and a DFU, tissue loss, or gangrene most beneÔ¨Åt
